Kiniksa announces positive data from phase II trial of mavrilimumab in giant cell arteritis

In RCT (n=70) of this investigational fully-human monoclonal antibody that targets GM-CSFRα, median time-to-flare by week 26 (primary efficacy endpoint) could not be estimated in mavrilimumab recipients due to low number of flares vs 25.1 weeks in placebo arm (HR 0.38, p=0.0263).

Source:

Biospace Inc.